Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IDEAL: A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)

NCT06060665 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT06060665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06060665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IDEAL: A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
September 5, 2023
Completion date
May 6, 2026
Enrollment
96 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cholangitis